Top Industry Leaders in the Nonallergic Rhinitis Market
Latest Nonallergic Rhinitis Companies Updates:
November 2018: AstraZeneca sold its rights to the asthma drug Alvesco (ciclesonide) and nasal sprays Omnaris and Zetonna (ciclesonide) to Covis Pharma for USD 350 million. This move allowed AstraZeneca to focus resources on developing new medications for unmet needs.
October 2023: Glenmark Pharmaceuticals launched its nasal corticosteroid spray, Flixonase Nasal Spray (fluticasone propionate), in the Indian market for the treatment of nonallergic rhinitis. This launch provides a new treatment option for Indian patients suffering from the condition.
June 2023: Sanofi received FDA approval for its nasal corticosteroid spray, Dymista (fluticasone propionate and azelastine hydrochloride), for the treatment of nonallergic rhinitis in adults and adolescents aged 12 years and older. This approval expands Dymista's reach beyond its previous indication for allergic rhinitis.
List of Nonallergic Rhinitis Key companies in the market:
- Pfizer Inc (U.S.)
- Progenics Pharmaceuticals (U.S.)
- GlaxoSmithKline (U.K.)
- Sucampo Pharmaceuticals Inc (U.S.)
- Ironwood Pharmaceuticals (U.S.)
- Sanofi (France)
- Salix Pharmaceuticals Ltd (U.S.)
- Bayer (Germany)